YOUR BUSINESS AUTHORITY

Springfield, MO

Log in Subscribe

Novartis bets $9.7B on cholesterol drug

Posted online

Novartis AG penned a $9.7 billion purchase deal for Medicines Co.

Bloomberg reports the acquisition focuses mostly on a single treatment: experimental cholesterol drug inclisiran.

Similarly, last year Novartis gained muscle disease gene therapy Zolgensma by buying drugmaker AveXis Inc. for $8.7 billion.

Read more from Bloomberg.

Comments

No comments on this story |
Please log in to add your comment
Editors' Pick
Letter to the Editor: No half-baked cake for our kids. No half-baked school grades, either.

Nixa Superintendent Gearl Loden weighs in on A-F grade cards.

Most Read
Update cookies preferences